Core Viewpoint - Four Seasons Pharmaceutical has received approval for six new specifications of its self-developed polylactic acid facial filler, enhancing its market position in the regenerative medical aesthetics sector [1] Group 1: Product Development and Approval - The newly approved specifications include 60mg, 80mg, 100mg, 110mg, 120mg, and 130mg bottles, expanding the product range beyond the previously approved 45mg, 75mg, and 150mg options [1] - The product, known as "童颜针" (Youthful Needle), utilizes PLLA microspheres to provide both immediate filling and long-lasting regeneration effects, with clinical efficacy lasting up to one year for most patients [1] Group 2: Market Positioning and Competitive Advantage - The addition of new specifications allows for precise matching of diverse anti-aging needs, covering a spectrum from mild to moderate aging, thus catering to different age groups and levels of aging [2] - The multi-specification approach strengthens Four Seasons Pharmaceutical's competitive edge in the rapidly growing global market for facial fillers, creating synergies with its other products like "少女针" (Girl Needle) and "双波射频" (Dual Wave RF) [2] Group 3: Clinical and Operational Benefits - The product's rapid reconstitution feature allows for flexible adjustments in dilution concentration and injection dosage, enhancing treatment efficiency and safety [2] - The expansion of specifications aligns with the industry's shift from standardized treatments to personalized solutions, guiding the sector towards higher quality and precision [2] Group 4: Market Strategy and Growth - Four Seasons Pharmaceutical plans to leverage its extensive network of over 7,000 medical institutions to quickly implement the new specifications in the market [3] - The company aims to drive innovation in aesthetic products by utilizing its pharmaceutical research capabilities, providing safer and more precise anti-aging solutions [3]

Core Viewpoint - Four Seasons Pharmaceutical (00460.HK) has received approval from the National Medical Products Administration for six new specifications of its self-developed polylactic acid facial filler, known as "童颜针" (Youthful Needle), marking a significant advancement in the company's market positioning within the regenerative aesthetic medicine sector [1] Group 1: Product Development - The newly approved specifications include 60mg, 80mg, 100mg, 110mg, 120mg, and 130mg bottles, which will enhance the product selection spectrum [1] - Prior to this expansion, the product had already been approved in three specifications: 45mg, 75mg, and 150mg bottles, catering to different needs such as preventive management, combination therapy, and comprehensive rejuvenation [1] Group 2: Competitive Advantage - Four Seasons Pharmaceutical is the only company in China that holds compliant regenerative filler products, specifically "少女针" (Girl Needle) and "童颜针" (Youthful Needle), along with three other major medical aesthetic devices: botulinum toxin, hydrating injections, and golden micro-needles [1] - The Youthful Needle utilizes a core component of L-lactic acid (PLLA) microspheres, achieving dual effects of "immediate filling + long-lasting regeneration," with patented technology ensuring uniform microsphere morphology and particle size, demonstrating excellent safety and clinical efficacy [1]

四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 關於渼顏空間 渼 顏 空 間 是 四 環 醫 藥 精 心 孵 化「一 站 式」新 型 醫 美 平 台，通 過 全 球 化 佈 局、全 面 專 業 的 醫 美 產 品 矩 陣、產 品 研 發、註 冊、生 產 及 銷 售 一 體 化 架 構，致 力 於 以 製 藥 企 業 的 嚴 謹 創 新 打 造 匠 心 鑄 造 中 國 醫 美 全 產 品 矩 陣 龍 頭 企 業。渼 顏 空 間 持 續 的 完 整 產 品 矩 陣，管 線 內 共 包 含60餘 款 產 品，覆 蓋 了 包 括 填 充、塑 形、支 撐、 光 電 設 備 及 皮 膚 管 理 類 等 輕 醫 美 的 基 礎 類 別。同 時，渼 ...

Group 1 - The core point of the article highlights that ST Huilun (300460) has faced regulatory penalties due to violations in information disclosure, specifically related to financial report inaccuracies from 2020 to 2022 [1][2] - On January 13, 2026, ST Huilun's stock closed at 8.91 yuan, down 1.22%, with a turnover rate of 7.32% and a trading volume of 205,600 shares, amounting to a transaction value of 184 million yuan [1] - The company received a total fine of 3 million yuan from the China Securities Regulatory Commission (CSRC) for failing to disclose significant financial information and for fabricating revenue and costs in its financial reports [1][2] Group 2 - On January 13, 2026, the net outflow of main funds was 17.58 million yuan, while retail and speculative funds showed a net inflow [2] - The company has stated that it has returned the occupied funds and that its production and operations are normal, indicating that the penalties do not lead to a situation of mandatory delisting due to major violations [1]

Core Viewpoint - ST Huilun has been penalized by the Guangdong Securities Regulatory Bureau for significant violations, including failure to disclose fund occupation and falsifying financial reports, resulting in a total fine of 11.4 million yuan [1][4]. Group 1: Violations - The company failed to disclose fund occupation matters in its 2020 annual report, with a total fund occupation amounting to 28.33 million yuan, which constituted 5.12% of the net assets disclosed in the report [2]. - ST Huilun inflated its revenue and costs in the 2021 and 2022 annual reports, with inflated revenues of 25.49 million yuan and 62.33 million yuan, representing 3.89% and 15.79% of the reported revenues for those years, respectively [3]. Group 2: Penalties - The Guangdong Securities Regulatory Bureau imposed a fine of 3 million yuan on ST Huilun and ordered corrective actions [4]. - The actual controller, Zhao Jiqing, was fined 4 million yuan for his direct involvement in the violations, while other executives received fines ranging from 60,000 to 1.5 million yuan [5][6]. Group 3: Company Background - ST Huilun is a national high-tech enterprise specializing in the research, production, and sales of new surface-mounted quartz crystal resonators, oscillators, and thermistors, listed on the Growth Enterprise Market since May 2015 [7]. - As of January 12, the company's stock price was 9.02 yuan per share, with a total market capitalization of 2.533 billion yuan [7].

Core Viewpoint - ST Huilun (300460) has faced regulatory penalties for information disclosure violations, impacting its financial reporting and leading to a total fine of 7 million yuan for the company and its actual controller [1][2]. Trading Information Summary - On January 12, ST Huilun closed at 9.02 yuan, up 10.27%, with a turnover rate of 11.33%, a trading volume of 318,100 shares, and a transaction value of 282 million yuan [1]. - The net inflow of main funds was 18.62 million yuan, indicating increased short-term interest from major investors [2]. Company Announcement Summary - The company and its actual controller, Zhao Jiqing, received an administrative penalty from the China Securities Regulatory Commission (CSRC) for failing to disclose fund occupation issues in 2020 and for inflating revenue and costs through fictitious transactions in 2021 and 2022 [1]. - The penalties included a fine of 3 million yuan for the company and 4 million yuan for Zhao Jiqing, with other responsible parties also receiving warnings and fines [1]. - The company has stated that it has returned the occupied funds and that its production and operations are normal, asserting that the penalties do not trigger major violations that would lead to forced delisting [1].

Core Viewpoint - ST Huilun has been penalized a total of 11.4 million yuan due to significant omissions and false records in its financial reports, as determined by the Guangdong Securities Regulatory Bureau [2][6]. Group 1: Violations - The company failed to disclose fund occupation matters in its 2020 annual report, with a total fund occupation amounting to 28.33 million yuan, which constituted 5.12% of the net assets disclosed in the report [5]. - In the 2021 and 2022 annual reports, ST Huilun inflated revenue by 25.49 million yuan and 62.33 million yuan respectively, representing 3.89% and 15.79% of the reported revenue for those years [5]. - The company also inflated total profits by 8.45 million yuan in 2021 and reduced profits by 1.41 million yuan in 2022, accounting for 6.13% and 0.91% of the reported total profits [5]. Group 2: Penalties - The Guangdong Securities Regulatory Bureau has ordered ST Huilun to rectify its practices, issued a warning, and imposed a fine of 3 million yuan on the company [6]. - The actual controller, Zhao Jiqing, was fined 4 million yuan and warned for his direct involvement in the violations [8]. - Other executives, including Han Qiaoyun and Deng Youqiang, received fines of 1.5 million yuan each, while other responsible personnel were fined between 60,000 and 800,000 yuan [9]. Group 3: Company Response - ST Huilun has expressed sincere apologies to investors and committed to improving internal governance, enhancing the quality of information disclosure, and complying with relevant laws and regulations [9]. - As of January 12, the company's stock price was 9.02 yuan per share, with a total market capitalization of 2.533 billion yuan [10].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 四環醫藥控股集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00460 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000 ...

四环医药(00460)发布公告，于2025年12月29日斥资1000.88万港元回购800万股。 ...

格隆汇12月29日丨四环医药(00460.HK)公告，12月29日耗资1000.9万港元回购800万股。 ...